Dear Sir, Please find the attachment. Regards, For MRC Agrotech Limited Compliance Officer/Authorised Signatory
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
MRC Agrotech's Board approved audited standalone and consolidated results for Q4 and FY ending 31 March 2026, with the auditor issuing an unqualified opinion. Full-year revenue from operations surged about 163% YoY to Rs. 85.46 crore (from Rs. 32.45 crore), while profit after tax rose roughly 33% to Rs. 1.17 crore (from Rs. 87.60 lakh). Q4 alone saw revenue jump over 200% YoY to Rs. 65.81 crore with PAT of Rs. 90.10 lakh. The company acquired Marsapi Lifesciences as a 100% subsidiary via a share-swap (86.42 lakh shares at Rs. 19.50, worth Rs. 16.85 crore) and assigned loans worth about Rs. 7.30 crore to Cicago Commodities on a non-recourse basis. The auditor flagged two Emphasis of Matter items and highlighted concerns around heavy revenue concentration in March 2026 and GST return classification.
Strong top-line growth is a positive, but profitability margins compressed meaningfully (FY EBITDA margin ~1.9% vs ~3.7% prior year) and operating cash flow fell sharply (Rs. 31 lakh vs Rs. 196 lakh), while trade receivables and payables ballooned — investors should watch collection quality, the new subsidiary's contribution, and whether the aggressive revenue ramp sustains margins.